Abstract
Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7α‐hydroxylasé activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl‐coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low‐density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7α‐hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy. (HEPATOLOGY 1995; 21:1025–1030.)
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1025-1030 |
| Number of pages | 6 |
| Journal | Hepatology |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1995 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Hepatology
Cite this
Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients : Reduced activity of cholesterol 7α‐hydroxylase. / Ståhlberg, Dagny; Reihnér, Eva; Rudling, Mats; Berglund, Lars; Einarsson, Kurt; Angelin, Bo.
In: Hepatology, Vol. 21, No. 4, 1995, p. 1025-1030.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients
T2 - Reduced activity of cholesterol 7α‐hydroxylase
AU - Ståhlberg, Dagny
AU - Reihnér, Eva
AU - Rudling, Mats
AU - Berglund, Lars
AU - Einarsson, Kurt
AU - Angelin, Bo
PY - 1995
Y1 - 1995
N2 - Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7α‐hydroxylasé activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl‐coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low‐density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7α‐hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy. (HEPATOLOGY 1995; 21:1025–1030.)
AB - Bezafibrate is a hypolipidemic fibric acid derivative known to induce cholesterol supersaturation of bile. To characterize its effects on hepatic cholesterol metabolism, 31 normolipidemic, normal‐weight patients with gallstones undergoing cholecystectomy were studied. Eleven patients (5 men) were randomized to treatment with bezafibrate, 200 mg three times daily for 4 weeks before operation; the remaining 20 patients (5 men) served as nontreatment controls. At operation, a liver biopsy specimen was obtained under standardized conditions and several important parameters of cholesterol metabolism were assayed. Bezafibrate treatment lowered total plasma cholesterol and triglycerides 30% and 37%, respectively. The hepatic cholesterol 7α‐hydroxylasé activity was reduced by ≈60% in the bezafibrate treated patients compared with the controls, whereas the acyl‐coenzyme A: cholesterol acyltransferase (ACAT) activity was similar in the two groups. The total 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG CoA) reductase activity was increased twofold in the treated patients, whereas the active enzyme remained about the same as in the controls. The low‐density lipoprotein (LDL) receptor binding activity was unaffected by the treatment. Bezafibrate treatment significantly reduces cholesterol 7α‐hydroxylase activity, and it is suggested that this may play an important role for the development of supersaturated bile during such therapy. (HEPATOLOGY 1995; 21:1025–1030.)
UR - http://www.scopus.com/inward/record.url?scp=84991145406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991145406&partnerID=8YFLogxK
U2 - 10.1002/hep.1840210421
DO - 10.1002/hep.1840210421
M3 - Article
VL - 21
SP - 1025
EP - 1030
JO - Hepatology
JF - Hepatology
SN - 0270-9139
IS - 4
ER -